Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

beta Amyloid Protein

Dieses Synthetic beta Amyloid-Protein wird in Synthetic produziert.
Produktnummer ABIN7272125

Kurzübersicht für beta Amyloid Protein (ABIN7272125)

Target

Alle beta Amyloid (Abeta) Proteine anzeigen
beta Amyloid (Abeta) (Amyloid beta (Abeta))

Protein-Typ

Synthetic

Spezies

Human

Quelle

  • 1
Synthetic

Applikation

Western Blotting (WB), In vitro Assay (in vitro), In vivo Studies (in vivo)

Reinheit

>95% pure using mass spec and HPLC.
  • Verwendungszweck

    Human Synthetic Amyloid Beta Peptide 1-42 (HFIP treated) Monomers

    Sequenz

    DAEFRHDSGY EVHHQKLVFF AEDVGSNKGA IIGLMVGGVV IA
  • Möchten Sie weitere Optionen für dieses Protein ?

    !
    Entdecken Sie unsere vordefinierten maßgeschneiderten Proteine und Proteinservices!

    Ihr Projekt erfordert weitere Anpassungen? Kontaktieren Sie uns und entdecken Sie unsere maßgeschneiderten Proteinlösungen

  • Applikationshinweise

    Optimal working dilution should be determined by the investigator.

    Beschränkungen

    Nur für Forschungszwecke einsetzbar
  • Lagerung

    -80 °C

    Informationen zur Lagerung

    -80°C
  • Target

    beta Amyloid (Abeta) (Amyloid beta (Abeta))

    Andere Bezeichnung

    Amyloid Beta

    Hintergrund

    Our amyloid beta peptide 1-42 (Aβ42) is produced synthetically and treated with 1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP) prior to drying which breaks down pre-formed fibrils and monomerizes the peptide, as previously published (1,2). Upon resuspension in DMSO/dH2O, our Aβ42 presents as a monomeric peptide without fibrils when observed under TEM, AFM and on a Western Blot with an anti-amyloid beta antibody. In contrast to AB42 oligomer and fibril constructs, our Aβ42 monomers were not toxic to primary rat cortical neurons. In the brain, amyloid beta peptide (Aβ) is generated by protease cleavage of amyloid precursor protein (APP), which aggregates into oligomers, protofibrils, fibrils and ultimately plaques in neurodegenerative diseases. The accumulation of Aβ plaques in the brain is considered a hallmark of Alzheimer's disease (AD), and most of the drugs tested for AD in the past 20 years have targeted amyloid beta accumulation (3). Soluble Aβ oligomers isolated from the brains of AD patients or those generated in vitro potently impaired synapse structure and function (4). Aβ oligomers generated in vitro were toxic to PC12 cells (2) and SH-SY5Y cells (5). Aβ was demonstrated to interact with tauopathies to affect neurodegeneration in AD patients (6) and accumulations of Aβ were shown to be associated with lower survival rates in Parkinson's disease patients with dementia (7)., cellular localisation: Cell Membrane , Intracellular Vesicles

    Molekulargewicht

    4.5 kDa

    Gen-ID

    351

    UniProt

    P05067

    Pathways

    Inflammasome
Sie sind hier:
Chat with us!